We have seen great strides in the approval of cancer immunotherapies, treatments that harness the powers of the immune system to battle cancer. Although recent breakthroughs in cancer immunotherapy have deepened our understanding of the mechanisms and pathways that regulate the immune's system response to cancer, the leading agents, the checkpoint inhibitors (CPIs), while demonstrating dramatic effects in certain cancers and patients, in other settings have shown only modest if not negligible clinical benefit. Hence there remains a high unmet need for additional therapies, in particular to be used in combination with CPIs to enhance activity, especially to reverse innate or acquired resistance. This panel will discuss the future of immuno-oncology and combination strategies, new generation of checkpoint inhibitors and novel mechanisms of action for immune engagement.
Session ID: 537270